Every 10-Q that Caribou Biosciences, Inc. (CRBU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRBU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRBU filings page.
Caribou Biosciences, Inc. reported continued operating losses while advancing its two allogeneic CAR-T programs, vispacabtagene regedleucel (vispa-cel) and CB-011, for hematologic malignancies. For the six months ended June 30, 2026, licensing and other revenue was $3.9 million and net loss was $49.4 million, a smaller loss than a year earlier largely due to lower research and development and general and administrative spending.
Cash, cash equivalents, and marketable securities totaled $113.8 million, and management expects this to fund the current operating plan for at least 12 months. Operating cash outflow was $49.8 million in the first half, partially offset by $20.1 million in net proceeds from at-the-market equity sales.
The company reached alignment with the FDA on ANTLER-3, a planned pivotal phase 3 trial of vispa-cel in second-line large B cell lymphoma, and reported updated phase 1 data for both vispa-cel and CB-011 showing high response rates and manageable safety profiles in selected subgroups.
Caribou Biosciences reported first-quarter 2026 results showing a narrower net loss as it continues to advance its allogeneic CAR-T pipeline. Licensing and other revenue was $2.4 million, while research and development and general and administrative expenses fell to $20.6 million and $8.1 million, respectively.
Net loss improved to $25.1 million from $40.0 million a year earlier, and operating cash use declined to $27.0 million. As of March 31, 2026, the company held $118.6 million in cash, cash equivalents, and marketable securities, which management believes will fund operations for at least 12 months while it prepares a pivotal phase 3 trial for vispa‑cel and expands CB‑011 development.
Caribou Biosciences (CRBU) filed its Q3 2025 10‑Q, showing licensing and collaboration revenue of $2.198 million and a net loss of $27.548 million for the quarter. For the nine months ended September 30, revenue was $7.218 million with a net loss of $121.637 million. Operating cash used year‑to‑date was $90.168 million.
Cash, cash equivalents, and marketable securities totaled $159.212 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months. The company recorded $12.150 million of impairment charges and a $9.158 million impairment of an equity investment year‑to‑date, and reduced an MSKCC success payments liability to zero following license termination. Restructuring actions included discontinuing two programs and a workforce reduction of about 32%, with $1.8 million in severance and $0.4 million in wind‑down costs.
Clinical updates highlighted vispa‑cel (CD19): in a 22‑patient confirmatory cohort, overall response rate was 82% with a 64% complete response and 51% 12‑month progression‑free survival. An optimized 35‑patient cohort showed an 86% overall response and 63% complete response. The company plans a randomized pivotal phase 3 evaluation in second‑line LBCL.
Caribou Biosciences reported a quarterly net loss of $54.1 million and a six-month net loss of $94.1 million, with licensing and collaboration revenue of $2.7 million for the quarter and $5.0 million for the six months ended June 30, 2025. Management reported cash, cash equivalents and marketable securities of $183.9 million as of June 30, 2025, which it expects will fund operations for at least the next 12 months.
The company announced a strategic pipeline prioritization that discontinues preclinical research and two programs (GALLOP and AMpLify) and reduced the workforce by 47 employees (~32%). It recorded $12.15 million of impairment charges and a $9.16 million impairment of its equity investment in Edge, remeasured the MSKCC success payments liability to zero following termination notice, and ended the quarter with total assets of $220.9 million and an accumulated deficit of $542.5 million.